Literature DB >> 18800761

Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity.

Bettina Proneth1, Irina D Pogozheva, Federico P Portillo, Henry I Mosberg, Carrie Haskell-Luevano.   

Abstract

The melanocortin-3 and -4 receptors (MC3R, MC4R) have been implicated in energy homeostasis and obesity. Whereas the physiological role of the MC4R is extensively studied, little is known about the MC3R. One caveat is the limited availability of ligands that are selective for the MC3R. Previous studies identified Ac-His-DPhe(p-I)-Arg-Trp-NH 2, which possessed partial agonist/antagonist pharmacology at the mMC3R while retaining full nanomolar agonist pharmacology at the mMC4R. These data allowed for the hypothesis that the DPhe position in melanocortin tetrapeptides can be used to examine ligand side-chain determinants important for differentiation of mMC3R agonist versus antagonist activity. A series of 15 DPhe (7) modified Ac-His-DPhe (7)-Arg-Trp-NH 2 tetrapeptides has been synthesized and pharmacologically characterized. Most notable results include the identification of modifications that resulted in potent antagonists/partial agonists at the mMC3R and full, potent agonists at the mMC4R. These SAR studies provide experimental evidence that the molecular mechanism of antagonism at the mMC3R differentiates this subtype from the mMC4R.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800761      PMCID: PMC2896811          DOI: 10.1021/jm800291b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  45 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  A frameshift mutation in MC4R associated with dominantly inherited human obesity.

Authors:  G S Yeo; I S Farooqi; S Aminian; D J Halsall; R G Stanhope; S O'Rahilly
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

3.  A frameshift mutation in human MC4R is associated with a dominant form of obesity.

Authors:  C Vaisse; K Clement; B Guy-Grand; P Froguel
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

4.  Targeted disruption of the melanocortin-4 receptor results in obesity in mice.

Authors:  D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

5.  A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse.

Authors:  A A Butler; R A Kesterson; K Khong; M J Cullen; M A Pelleymounter; J Dekoning; M Baetscher; R D Cone
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

6.  The cloning of a family of genes that encode the melanocortin receptors.

Authors:  K G Mountjoy; L S Robbins; M T Mortrud; R D Cone
Journal:  Science       Date:  1992-08-28       Impact factor: 47.728

7.  Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor.

Authors:  D Lu; D Willard; I R Patel; S Kadwell; L Overton; T Kost; M Luther; W Chen; R P Woychik; W O Wilkison
Journal:  Nature       Date:  1994-10-27       Impact factor: 49.962

8.  Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain.

Authors:  K G Mountjoy; M T Mortrud; M J Low; R B Simerly; R D Cone
Journal:  Mol Endocrinol       Date:  1994-10

9.  A colorimetric assay for measuring activation of Gs- and Gq-coupled signaling pathways.

Authors:  W Chen; T S Shields; P J Stork; R D Cone
Journal:  Anal Biochem       Date:  1995-04-10       Impact factor: 3.365

10.  Structure-activity relationships of the melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH(2) at the mouse melanocortin receptors. 1. Modifications at the His position.

Authors:  Jerry Ryan Holder; Rayna M Bauzo; Zhimin Xiang; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2002-06-20       Impact factor: 7.446

View more
  12 in total

1.  Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R).

Authors:  Anamika Singh; Marvin Dirain; Rachel Witek; James R Rocca; Arthur S Edison; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2013-03-25       Impact factor: 7.446

Review 2.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

3.  Implication of the melanocortin-3 receptor in the regulation of food intake.

Authors:  Boman G Irani; Zhimin Xiang; Hossein N Yarandi; Jerry R Holder; Marcus C Moore; Rayna M Bauzo; Bettina Proneth; Amanda M Shaw; William J Millard; James B Chambers; Stephen C Benoit; Deborah J Clegg; Carrie Haskell-Luevano
Journal:  Eur J Pharmacol       Date:  2011-01-01       Impact factor: 4.432

4.  Replacement of Arg with Nle and modified D-Phe in the core sequence of MSHs, Ac-His-D-Phe-Arg-Trp-NH2, leads to hMC1R selectivity and pigmentation.

Authors:  Saghar Mowlazadeh Haghighi; Yang Zhou; Jixun Dai; Jonathon R Sawyer; Victor J Hruby; Minying Cai
Journal:  Eur J Med Chem       Date:  2018-04-11       Impact factor: 6.514

5.  Discovery of Melanocortin Ligands via a Double Simultaneous Substitution Strategy Based on the Ac-His-dPhe-Arg-Trp-NH2 Template.

Authors:  Aleksandar Todorovic; Cody J Lensing; Jerry Ryan Holder; Joseph W Scott; Nicholas B Sorensen; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-06-11       Impact factor: 4.418

6.  Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist.

Authors:  Zhimin Xiang; Bettina Proneth; Marvin L Dirain; Sally A Litherland; Carrie Haskell-Luevano
Journal:  Biochemistry       Date:  2010-06-08       Impact factor: 3.162

7.  Melanocortin antagonist tetrapeptides with minimal agonist activity at the mouse melanocortin-3 receptor.

Authors:  Skye R Doering; Aleksandar Todorovic; Carrie Haskell-Luevano
Journal:  ACS Med Chem Lett       Date:  2014-12-29       Impact factor: 4.345

8.  Azepinone-Containing Tetrapeptide Analogues of Melanotropin Lead to Selective hMC4R Agonists and hMC5R Antagonist.

Authors:  Olivier Van der Poorten; Krisztina Fehér; Koen Buysse; Debby Feytens; Ioanna Zoi; Steven D Schwartz; José C Martins; Dirk Tourwé; Minying Cai; Victor J Hruby; Steven Ballet
Journal:  ACS Med Chem Lett       Date:  2014-12-03       Impact factor: 4.345

9.  Discovery of Mixed Pharmacology Melanocortin-3 Agonists and Melanocortin-4 Receptor Tetrapeptide Antagonist Compounds (TACOs) Based on the Sequence Ac-Xaa1-Arg-(pI)DPhe-Xaa4-NH2.

Authors:  Skye R Doering; Katie T Freeman; Sathya M Schnell; Erica M Haslach; Marvin Dirain; Ginamarie Debevec; Phaedra Geer; Radleigh G Santos; Marc A Giulianotti; Clemencia Pinilla; Jon R Appel; Robert C Speth; Richard A Houghten; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2017-05-15       Impact factor: 7.446

10.  Synthesis and Structure-Activity Relationships of Substituted Urea Derivatives on Mouse Melanocortin Receptors.

Authors:  Anamika Singh; Johannes Kast; Marvin L S Dirain; Huisuo Huang; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2015-12-24       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.